Why the study?
When primary angioplasty is unavailable, thrombolysis is appropriate for acute myocardial infarction, prompting evaluation of the safety and effectiveness of tenecteplase versus alteplase in STEMI.
Key points are not available for this paper at this time.
Population
Patients with STEMI
Comparison
Tenecteplase (TNKase) vs alteplase
Design
Systematic review and meta-analysis
Answers are grounded in this paper and cite their sources.
Tenecteplase matches alteplase efficacy with lower bleeding in STEMI; reinforces single-bolus preference when fibrinolysis is indicated.
Background & Objective: If primary angioplasty is not available, thrombolytic therapy is an appropriate option for the treatment of acute myocardial infarction (AMI) in the early hours after the beginning of the signs. This study aimed to assess the safety and effectiveness of tenecteplase (TNKase) vs. alteplase in the treatment of ST-elevation myocardial infarction (STEMI).
No takes yet. Share an insight, caveat, or question.
Bashzar et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: